X
[{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Announces Positive Data From Clinical Study with ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure gets abstract on the NeuroRestore platform against Alzheimer's accepted for poster presentation at CTAD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Receives Approval to Start Clinical PhaseII Trial with ACD856 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure\u2019s Alzheimer Project Has Initiated the Next Clinical Phase I Study With ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data from the Clinical Phase I MAD study with AlzeCure's Alzheimer's Project NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Receives US Patent for NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure's Alzheimer\u2019s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Presented at Alzheimer's Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure is Granted European Patent for NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"AlzeCure Pharma AB"},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Recruited Into Alzinova's Phase 1b Clinical Study with The Oligomer-Specific ALZ-101 Vaccine Against Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Alzinova"},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Improves Manufacturing Process of ALZ-101 to Meet Phase 2 Requirements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Alzinova"},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Announces Positive Safety Review and Continuation of its Phase 1b study in Alzheimer's disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Alzinova"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Emplicure"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Published on ABBV-0805 in Neurobiology of Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$755.0 million","upfrontCash":"$80.0 million","newsHeadline":"AbbVie Terminates Collaboration with BioArctic on alpha-Synuclein Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioarctic Receives New Drug Substance Patent in the US for ABBV-0805 Against Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BioArctic AB"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexo"}]
Find Neurology Drugs in Phase I Clinical Development in SWEDEN
Filters
Details:
ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF and NGF. EPO has granted a patent covering Alzheimer'sdisease and other disorders with cognitive impairment.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 22, 2023
Details:
A positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, ACD856 has been shown in preclinical studies to improve cognition and memory and is poised for Phase 2 clinical trials, where it is being developed primarily for the treatment of Alzheimer's disease .
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2022
Details:
Presentation contains results from the clinical phase I MAD study with ACD856, A novel positive allosteric modulator of Trk-signaling within the NeuroRestore platform, which exhibits both good tolerability and good pharmacokinetic properties in humans.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 24, 2022
Details:
ACD856, which is a positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, has demonstrated in preclinical studies to improve cognition and memory and is ready for phase 2 clinical studies for the treatment of Alzheimer's disease.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 11, 2022
Details:
ACD856 increases EEG activity in the brain. This result show that the substance not only crosses the blood-brain barrier, but also reaches and activates neural pathways in the brain, with the potential of having positive effects on cognition.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 16, 2022
Details:
ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 08, 2022
Details:
EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine.
Lead Product(s):
Buprenorphine
Therapeutic Area: Neurology
Product Name: EMPLI03
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Quotient Sciences
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 27, 2022
Details:
Data show that ACD856, primary drug candidate has good tolerability and safety. Furthermore, the results demonstrate that the substance has suitable pharmacokinetic properties with rapid uptake into the body as well as relevant and dose-dependent exposure in the CNS.
Lead Product(s):
ACD856
Therapeutic Area: Neurology
Product Name: ACD856
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 29, 2022
Details:
The granted substance patent focuses on the monoclonal antibody ABBV-0805, which selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while sparing the physiological monomer form of alpha-synuclein.
Lead Product(s):
ABBV-0805
Therapeutic Area: Neurology
Product Name: ABBV-0805
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 06, 2022
Details:
As specified in the ALZ-101, an active, therapeutic oligomer-specific vaccine study protocol, the DSMB meets periodically to examine the safety data accumulated during progress of the study.
Lead Product(s):
ALZ-101
Therapeutic Area: Neurology
Product Name: ALZ-101
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 28, 2022